Therapeutic Area | MeSH |
---|---|
respiratory tract diseases | D012140 |
cardiovascular diseases | D002318 |
Brand Name | Status | Last Update |
---|---|---|
bidil | New Drug Application | 2020-07-29 |
hydralazine | ANDA | 2022-02-15 |
hydralazine hcl | ANDA | 2019-04-30 |
hydralazine hydrochloride | ANDA | 2024-01-30 |
hydralazine hydrocloride | 2006-09-19 |
Code | Description |
---|---|
J0360 | Injection, hydralazine hcl, up to 20 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 3 | 1 | 2 | 4 | 11 | 21 |
Heart failure | D006333 | HP_0001635 | I50 | 1 | 3 | 3 | 4 | 6 | 16 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 2 | 3 | 6 |
Postoperative pain | D010149 | — | G89.18 | — | 3 | 2 | 2 | — | 5 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | 2 | 3 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 2 | — | 2 |
Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | 1 | 1 | 2 |
Neuromuscular blockade | D019148 | — | — | — | — | — | 1 | 1 | 2 |
Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | 1 | 2 |
Cardiogenic shock | D012770 | — | R57.0 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Uterine cervical neoplasms | D002583 | HP_0030159 | — | — | 1 | 2 | — | 2 | 5 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | 1 | — | 1 | 3 |
Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | 2 | 3 |
Pregnancy-induced hypertension | D046110 | — | O13 | — | 1 | 1 | — | 1 | 3 |
Polycystic kidney diseases | D007690 | HP_0000113 | Q61.3 | 1 | — | 1 | — | — | 2 |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | 1 | 2 |
Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | 2 | — | — | 2 |
Ectopic pregnancy | D011271 | — | O00 | 1 | 1 | 1 | — | — | 2 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 1 | — | 1 | 2 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | — | — | 3 | 5 |
Cerebral hemorrhage | D002543 | — | — | — | 2 | — | — | 2 | 4 |
Myelodysplastic syndromes | D009190 | — | D46 | — | 3 | — | — | — | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | 2 | 3 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | 2 | 3 |
Blood pressure | D001794 | EFO_0004325 | — | 1 | 1 | — | — | — | 2 |
Rectal neoplasms | D012004 | — | — | 1 | 2 | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | — | 2 | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | — | — | — | 2 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | 2 | 3 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | 2 | 3 |
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | 2 | 3 |
Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | — | — | 1 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | — | — | — | — | 1 |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | — | — | — | — | 1 |
Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | — | — | — | — | 1 |
Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Nasal polyps | D009298 | HP_0100582 | J33 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 6 | 6 |
Anesthesia | D000758 | — | — | — | — | — | — | 3 | 3 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 3 | 3 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 2 | 2 |
Delirium | D003693 | — | R41.0 | — | — | — | — | 2 | 2 |
Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 2 | 2 |
Trisomy 18 syndrome | D000073842 | — | Q91.3 | — | — | — | — | 2 | 2 |
Trisomy 13 syndrome | D000073839 | — | Q91.7 | — | — | — | — | 2 | 2 |
Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 2 | 2 |
Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
Drug common name | Hydralazine |
INN | hydralazine |
Description | Hydralazine is the 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent. It has a role as an antihypertensive agent and a vasodilator agent. It is a member of phthalazines, an azaarene, an ortho-fused heteroarene and a member of hydrazines. |
Classification | Small molecule |
Drug class | antihypertensives (hydrazine-phthalazines); antiarrhythmic/antianginal/antihypertensive agents, phthalazine like structure |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NNc1nncc2ccccc12 |
PDB | — |
CAS-ID | 86-54-4 |
RxCUI | — |
ChEMBL ID | CHEMBL276832 |
ChEBI ID | 5775 |
PubChem CID | 3637 |
DrugBank | DB01275 |
UNII ID | 26NAK24LS8 (ChemIDplus, GSRS) |